title: 18F-FDG PET and PET/CT in Burkitt's lymphoma.
abstract: OBJECTIVE
  To explore the value of (18)F fluorodeoxy-glucose (FDG) positron emission tomography (PET) in Burkitt's lymphoma.
  
  
  METHODS
  All Burkitt's lymphoma patients referred for FDG PET or FDG PET/computed tomography (CT) exams at our institution from June 2003 to June 2006 were included. Selected patients were followed and clinical information was reviewed retrospectively. Results from FDG PET-PET/CT, as blindly reviewed by a consensus of two experienced readers, were compared with the status of the disease as determined by other laboratory, clinical and imaging exams and clinical follow-up. FDG PET-PET/CT results were classified as true positive or negative and false positive or negative. The degree of FDG uptake in the positive lesions was semiquantified as maximum standard uptake value (SUVmax).
  
  
  RESULTS
  Fifty-seven FDG PET-PET/CT exams were done in 15 patients. Seven exams were done for initial staging, 8 during and 14 after the completion of therapy, and 28 for disease surveillance. For nodal disease FDG PET-PET/CT was true positive in 8, true negative in 47 and false positive in 2 exams (sensitivity 100%, specificity 96%). For extranodal disease FDG PET-PET/CT was true positive in 6, true negative in 48 and false positive in 3 exams (sensitivity 100%, specificity 94%). The mean SUVmax for the positive nodal lesions was 15.7 (range 6.9-21.7, median 18.5) and for extranodal lesions was 14.2 (range 6.2-24.3, median 12.4).
  
  
  CONCLUSIONS
  FDG PET-PET/CT is sensitive for the detection of viable disease in Burkitt's lymphoma. Affected areas demonstrated high degree of uptake that was reversible upon successful implementation of treatment.
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, USA. dkarantanis@nuclmed.net
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Karantanis
authors.forename: Jolanta M
authors.initials: JM
authors.lastname: Durski
authors.forename: Val J
authors.initials: VJ
authors.lastname: Lowe
authors.forename: Mark A
authors.initials: MA
authors.lastname: Nathan
authors.forename: Brian P
authors.initials: BP
authors.lastname: Mullan
authors.forename: Evangelos
authors.initials: E
authors.lastname: Georgiou
authors.forename: Patrick B
authors.initials: PB
authors.lastname: Johnston
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Wiseman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002051:Burkitt Lymphoma / Q000175:diagnosis*; D002648:Child; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013382:Subtraction Technique; D014057:Tomography, X-Ray Computed / Q000379:methods*; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18